CTI
BioPharma Corp. (Nasdaq: CTIC) reported positive data from a Phase 3
registration-directed trial of pacritinib to treat myelofibrosis lifting the stock price 39 cents to $2.33.
Positive data from CTI BioPharma
June 01, 2015 at 06:54 AM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.